SavedAdd your journal

Journals / Journal of Neurological Sciences (Turkish) / 2011 / Cilt: 28 - Sayı: 4

Rıvastıgmıne Transdermal Flastere Bağlı Vaskülitik Deri Döküntüsü: Bir Olgu Sunumu

Vasculitic Skin Eruption Due To Rivastigmine Patch: A Case Report

Cem ÇOMUNOĞLU
Amber EKER
F. Aslı KAPTANOĞLU
H. İlker İPEKDAL
Pages
599–603
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This is the first case of rivastigmine transdermal patch inducedvasculitic skin eruption which was located in both application and non-application sites.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Rivastigmine transdermal patches can provide non-invasive, continuous drug delivery, andoffer significant potential advantages over oral treatments.
📊
Key Findings & Data:A 75-years old female patientdeveloped itching after the initiation of rivastigmine transdermal patch.
💡
Conclusion & Impact:This is the first case of rivastigmine transdermal patch inducedvasculitic skin eruption which was located in both application and non-application sites.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Rivastigmine transdermal patches can provide non-invasive, continuous drug delivery, andoffer significant potential advantages over oral treatments. However, the most common sideeffects of transdermal patch form is local skin reactions. A 75-years old female patientdeveloped itching after the initiation of rivastigmine transdermal patch. Multiple,erythematous infiltrated annular plagues with significant borders (identical in shape with thepatch) and generalised, excoriated erythematous papules, in addition to the lichenificatedexcoriated plaques on both legs were detected in her physical examination. Histopathologicalexamination of the skin biopsy which was performed from the lesions revealedleucocytoclastic vaculitis showing spongiosis and leucocyte deposition around the vessels.She responded to topical potent steroids and systemic antihistamines and recoveredcompletely within a month. This is the first case of rivastigmine transdermal patch inducedvasculitic skin eruption which was located in both application and non-application sites.

Özet

Rivastigmine transdermal flasterler, ilacın sürekli ve non-invaziv verilmesini sağlamalarısayesinde ağız yoluyla verilen tedavilere nazaran önemli üstünlük sergilemektedirler. Bununlabirlikte, transdermal flasterin en sık görülen yan etkisi lokal cilt reaksiyonlarıdır. 75 yaşındakibir bayan hastada, rivastigmin flaster uygulamasının ardından kaşıntı gelişti. Fizikmuayenesinde, keskin sınırları olan (flasterin şekli ile özdeş) yuvarlak, çok sayıda eritematözplaklara ve bacaklardaki likenifiye ekskoriasyonlu plaklara ek olarak jeneralizeekskoriasyonlu eritematöz papüller tespit edildi. Topikal potent steroidlere ve sistemikantihistaminiklere cevap veren hasta, bir ay içerisinde tamamen düzeldi. Bu olgu, rivastigmintransdermal flasterin neden olduğu, hem uygulama bölgesinde hem de uygulama bölgesinindışında lokalize olan ilk vaskülitik cilt döküntüsü olgusudur.

🔖

Cite This Article

ÇOMUNOĞLU, C., EKER, A., KAPTANOĞLU, F. A., İPEKDAL, H. İ. (2022). Rıvastıgmıne Transdermal Flastere Bağlı Vaskülitik Deri Döküntüsü: Bir Olgu Sunumu. Journal of Neurological Sciences (Turkish), Cilt: 28 - Sayı: 4, 599–603. https://ajindex.com/articles/565374

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Adebayo PB, Alebiosu OC. ACE-I induced angioedema: a case report and review of literature. Cases J. 2009;2:7181
  2. Bewley AP, Feher MD, Staughton RC. Erythema multif orme f ollowing substitution of amlodipine f or nif edipine. BMJ. 1993;307(6898):241
  3. Broski SE, Regan TD, Sturgill WH. Case reports: lisinopril-induced erythroderma in an 85-year-old male. J Drugs Dermatol. 2008;7(2):163-6
  4. Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Investig 2010;30(1):41-9
  5. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence- based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–66
  6. Eichelberg D, Stolze P, Block M, Buchkremer G. Contact allergies induced by TTS-treatment. Methods Find Exp Clin Pharmacol. 1989;11(3):223- 5
  7. Emre M, Bernabei R, Blesa R, et al. Drug prof ile: transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther. 2010;16(4):246-53
  8. Grieco T, Rossi M, Faina V, De Marco I, Pigatto P, Calvieri S. An atypical cutaneous reaction to rivastigmine transdermal patch. J Allergy (Cairo) 2011;2011:752098
  9. Hong JA, Bisognano JD. Metoprolol succinate therapy associated with erythema multif orme. Cardiol J. 2009;16(1):82-3
  10. Mancuso G, Berdondini RM, Passarini B. Eosinophilic pustular eruption associated with transdermal f entanyl. J Eur Acad Dermatol Venereol. 2001;15(1):70-2
  11. Musel AL, Warshaw EM. Cutaneous reactions to transdermal therapeutic systems. Dermatitis. 2006;17(3):109-22
  12. Polster AM, Warner MR, Camisa C. Allergic contact dermatitis f rom transdermal clonidine in a patient with mycosis f ungoides. Cutis. 1999;63(3):154-5
  13. Sadowsky CH, Farlow MR, Meng X, Olin JT. Saf ety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched f rom donepezil: data f rom three clinical trials. Int J Clin Pract. 2010;64(2):188-93
  14. Shouls J, Shum KW, Gadour M, Gawkrodger DJ. Contact allergy to testosterone in an androgen patch: control of symptoms by pre-application of topical corticosteroid. Contact Dermatitis. 2001;45(2):124-5
  15. Stoukides CA, Stegman M. Diff use rash associated with transdermal f entanyl. Clin Pharm. 1992;11(3):222
  16. Winblad B, Cummings J, Andreasen N, et al. A six- month